An update from Mineralys Therapeutics, Inc. ( (MLYS) ) is now available. Mineralys Therapeutics announced that the U.S. FDA ...

India-based Suven Life Sciences has announced the dosing of the first subjects in its Phase I clinical trial of SUVN-I6107 to ...

NEW YORK, NY, UNITED STATES, January 9, 2025 /EINPresswire / -- Antelope Surgical Solutions, Inc., a biotechnology company pioneering next-generation multimodal radiopharmaceuticals, and SHINE ...

Nimbus Therapeutics Announces Clinical Progress in Oncology Therapeutic Pipeline and Provides Business Updates ...

ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to ...

SAN FRANCISCO, Jan. 9, 2025 /PRNewswire/ -- BioAge Labs (NASDAQ: BIOA ) , a biopharmaceutical company focused on metabolic diseases, is facing a class-action lawsuit from shareholders who allege the ...

MOMA Therapeutics on Wednesday said it added the next-generation PARP1 inhibitor MOMA-989 to its pipeline of drug candidates and anticipates filing an investigational new drug application by year end ...

NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 43 rd ...

Results from the investigational, randomized, open-label IRAKLIA phase 3 study demonstrated that Sarclisa administered at a fixed dose subcutaneously (SC) via an on-body delivery system (OBDS) in ...

Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad ...

Hyderabad: Suven Life Sciences, a clinical stage biopharmaceutical company discovering and developing novel medicines to ...

Charlestown, Massachusetts Thursday, January 9, 2025, 14:30 Hrs [IST] ...